Searchable abstracts of presentations at key conferences in endocrinology

ea0099oc13.1 | Oral Communications 13: Late Breaking | ECE2024

BCL2 expression is enriched in androgen receptor-negative advanced prostate cancer:

Jimenez-Vacas Juan M , Westaby Daniel , Figueiredo Ines , Rekowski Jan , Pettinger Claire , Gurel Bora , Bogdan Denisa , Buroni Lorenzo , Neeb Antje , Padilha Ana , Taylor Joe , Zeng Wanting , Das Souvik , Hobern Emily , Riisnaes Ruth , Crespo Mateus , Miranda Susana , Ferreira Ana , Hanratty Brian , Nava Rodrigues Daniel , Bertan Claudia , Seed George , Fenor de La Maza Maria de Los Dolores , Guo Christina , Carmichael Juliet , Grochot Rafael , Chandran Khobe , Stavridi Anastasia , Varkaris Andreas , Stylianou Nataly , Hollier Brett , Tunariu Nina , Balk Steven , Carreira Suzanne , Yuan Wei , Nelson Peter , Corey Eva , Haffner Michael , de Bono Johann , Sharp Adam

Background: Treatment resistance in prostate cancer can be the result of multiple different tumour cell adaptations generating castration-resistant prostate cancer (CRPC). Despite advancements in treatment, CRPC remains a highly lethal disease. Some CRPCs become AR independent with loss of AR expression and lineage plasticity, urgently requiring novel therapeutic strategies. BCL2 can be upregulated in some CRPCs and may be a therapeutic target for this disease subset.<p cl...